Nanna Lüneborg, Ph.D., MBA

Nanna is a General Partner at Forbion, where she is part of the senior leadership of the Forbion Growth strategy, focusing on clinical stage investments. She has prior investment experience from Novo Holdings, where she was a Partner in the Venture Investment team, and Apposite Capital, where she was an Associate. 

Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Capstan (acquired by AbbVie), Inversago (acquired by Novo Nordisk), Numab (asset sale of Yellow Jersey spin-out to J&J), ReViral (acquired by Pfizer), Lava Therapeutics (LVTX), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA) and NodThera. In addition to the Maplight board, Nanna is currently on the board of Sparrow Pharma, F2G, BioInvent (BINV), Noema Pharma, and a board observer of Numab and Azafaros. 

Nanna has a PhD in Neuroscience from University College London, an MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford.